Literature DB >> 7636552

Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.

M M Heiss1, R Babic, H Allgayer, K U Gruetzner, K W Jauch, U Loehrs, F W Schildberg.   

Abstract

PURPOSE: The significance of tumor-associated proteolysis as reflected by parameters of the urokinase-type plasminogen activator (uPA) system for prognosis in cancer patients has been proposed because of evidence for its central role in basic mechanisms of invasion and metastasis. The aim of the present study was to evaluate whether the expression of the uPA parameters might be of clinical value in gastric cancer as a tumor/biologically defined risk factor. PATIENTS AND METHODS: In a consecutive series of 203 patients resected for primary gastric cancer, the expression of uPA, uPA-receptor (uPA-R), plasminogen activator inhibitor (PAI)-1, and PAI-2 was determined immunohistochemically. The results were classified semiquantitatively (0 to 3). Patients were followed-up prospectively for a median of 31 months (range, 9 to 56 months). Disease-free and overall survival were analyzed according to Kaplan-Meier and with univariate and multivariate Cox analyses in relation to conventional prognostic factors.
RESULTS: Univariate analyses revealed a highly significant inverse correlation of uPA, uPA-R, and PAI-1 expression with survival time (P = .0008, P = .0002, and P = .0002, respectively), whereas PAI-2 demonstrated only a weak correlation. In multivariate analyses, PAI-1 was an independent and strong prognostic factor (P = .005; relative risk, 1.47 per staining degree; 95% confidence interval [CI], 1.31 to 1.64). In pT1/2 tumors and in Laurén's diffuse and mixed types, uPA, uPA-R, and PAI-1 added significant prognostic information. PAI-1 was also associated with survival in the subgroup of lymph node-positive patients.
CONCLUSION: PAI-1, uPA, and uPA-R are new functional risk factors reflecting clinical prognosis. In particular, PAI-1 is a new independent variable for the identification of patients at high risk after tumor resection. Our results support the hypothesis that the uPA system probably is of general importance for prognosis of patients with malignant disease, indicating an individual tumor's capacity for invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636552     DOI: 10.1200/JCO.1995.13.8.2084

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  17 in total

1.  Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer.

Authors:  Lori J Goldstein
Journal:  Breast Care (Basel)       Date:  2008-10-16       Impact factor: 2.860

Review 2.  [Oncology '96].

Authors:  F Hartmann; M Pfreundschuh
Journal:  Med Klin (Munich)       Date:  1997-02-15

3.  Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.

Authors:  M Plebani; L Herszènyi; P Carraro; M De Paoli; G Roveroni; R Cardin; Z Tulassay; R Naccarato; F Farinati
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

4.  Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.

Authors:  Feng Ji; Yue-Liang Chen; En-Yun Jin; Wei-Lin Wang; Zi-Li Yang; You-Ming Li
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

5.  Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells.

Authors:  Kristin G Nørsett; Islay Steele; Cedric Duval; Stephen J Sammut; Senthil V M Murugesan; Susan Kenny; Lucille Rainbow; Rod Dimaline; Graham J Dockray; D Mark Pritchard; Andrea Varro
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-30       Impact factor: 4.052

6.  Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.

Authors:  M M Heiss; H Allgayer; K U Gruetzner; R Babic; K W Jauch; F W Schildberg
Journal:  Ann Surg       Date:  1997-12       Impact factor: 12.969

7.  Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.

Authors:  H Allgayer; R Babic; K U Grützner; B C Beyer; A Tarabichi; F W Schildberg; M M Heiss
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 5.150

8.  TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.

Authors:  Tao Zhang; Bofang Wang; Fei Su; Baohong Gu; Lin Xiang; Lei Gao; Peng Zheng; Xue-Mei Li; Hao Chen
Journal:  Int J Biol Sci       Date:  2022-07-11       Impact factor: 10.750

9.  Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers.

Authors:  Oscar Vidal; Antonio Soriano-Izquierdo; Manuel Pera; José I Elizalde; Antonio Palacín; Antoni Castells; Josep M Piqué; Alain Volant; Jean P Metges
Journal:  J Gastrointest Surg       Date:  2007-10-31       Impact factor: 3.452

10.  The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO2 pneumoperitoneum.

Authors:  Petra Krause; Nina S Bobisch; Paul Thelen; Karola Koehler; Sarah Koenig; Heinz Becker; Ingo Leister
Journal:  Int J Colorectal Dis       Date:  2010-10-08       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.